Delcath Systems Inc. relocated its headquarters from Stamford to New York City, citing easier access to investors and medical institutions with which it does business.
After a public spat with investor LaddCap Value Partners, M.S. Koly resigned last December as chief executive officer of Delcath. He was replaced by Richard Taney, who runs a New York investment firm.
At last report, the publicly traded company had a half-dozen employees, including Samuel Herschkowitz, Delcath”™s chief operating officer who is a professor at New York University Medical Center.
The company is developing a method to deliver drugs to the liver and other specific body organs that have cancer, which it says would cut side effects from chemotherapy.
Since its 1988 inception, the company has accumulated $39 million in net losses.
Â
